Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

Table 2 Baseline characteristics and demographics of randomized patients, n (%)

	CDDP (n = 362)	Placebo (n = 121)	P value
Demographics
Gender (male/female)	192/170	59/62	0.415
Age (years)	58.22 (8.13)	57.22 (8.01)	0.196
Positive pregnancy test (women only)	0 (0.00)	0 (0.00)	0.971
Height (m)	1.65 (0.08)	1.65 (0.08)	0.733
Weight (kg)	65.86 (10.70)	65.85 (10.10)	0.877
BMI (kg/m2)	24.11 (2.93)	24.24 (2.94)	0.662
Treatment for diabetes
Duration of diabetes (years)	10.42 (5.90)	10.01 (6.07)	0.382
Sulfonylureas preparation	98 (27.84)	29 (24.58)	0.489
Biguanides preparation	148 (42.05)	49 (41.53)	0.921
Alpha-glucosidase inhibitor	116 (32.95)	33 (27.97)	0.314
Insulin	179 (50.85)	62 (52.54)	0.751
Other diabetes medications	48 (13.64)	12 (10.17)	0.329
HbA1c (%)	6.89 (0.95)	6.96 (0.92)	0.454
Duration of DR (years)	2.31 (2.85)	2.44 (3.06)	0.662
Retinopathy level in worst eye (ETDRS scale)			0.437
No obvious diabetic retinopathy	0 (0.00)	0 (0.00)
Mild NPDR	127 (35.08)	48 (39.67)
Moderate NPDR	182 (50.28)	56 (46.28)
Severe NPDR	53 (14.64)	17 (14.05)
PDR	0 (0.00)	0 (0.00)
General ophthalmologic examination
Left eye’s corrected vision (Snellen's test-chart)	4.71 (0.47)	4.76 (0.46)	0.099
Right eye’s corrected vision (Snellen's test-chart)	4.72 (0.47)	4.78 (0.40)	0.113
Fundus changes
Microaneurysms	362 (100)	121 (100)	> 0.999
Hemorrhage	115 (34.53)	44 (38.94)	0.398
Hard exudates	137 (41.14)	39 (34.51)	0.213
Microvascular abnormalities			0.178
No abnormality	306 (84.53)	102 (84.30)
Mild abnormality	31 (8.56)	7 (5.79)
Severe abnormality	25 (6.91)	12 (9.92)
Venous beading	6 (1.66)	2 (1.65)	> 0.999
Diabetic macular edema	59 (21.15)	19 (21.59)	0.929
Neovascularization	0 (0.00)	0 (0.00)	> 0.999

BMI: Body mass index; DR: Diabetic retinopathy; ETDRS: Early treatment diabetic retinopathy study; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy.